nilotinib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 1932 641571-10-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nilotinib hydrochloride hydrate
  • nilotinib
  • tasigna
  • nilotinib hydrochloride monohydrate
Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation of the kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murine leukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of the assays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 out of 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.
  • Molecular weight: 529.53
  • Formula: C28H22F3N7O
  • CLOGP: 5.69
  • LIPINSKI: 2
  • HAC: 8
  • HDO: 2
  • TPSA: 97.62
  • ALOGS: -5.42
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 21.58 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 29, 2007 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic myeloid leukaemia 514.01 14.88 133 20257 2581 53326095
Cytogenetic analysis abnormal 501.72 14.88 103 20287 661 53328015
Peripheral arterial occlusive disease 342.08 14.88 105 20285 3849 53324827
Electrocardiogram QT prolonged 313.57 14.88 220 20170 56183 53272493
Blast crisis in myelogenous leukaemia 224.58 14.88 50 20340 492 53328184
Second primary malignancy 203.42 14.88 83 20307 7049 53321627
Chronic myeloid leukaemia transformation 183.41 14.88 34 20356 115 53328561
Lipase increased 172.17 14.88 80 20310 9298 53319378
Drug resistance 165.15 14.88 100 20290 19862 53308814
Rash 156.17 14.88 447 19943 445744 52882932
Pleural effusion 135.41 14.88 168 20222 88411 53240265
Philadelphia chromosome positive 127.98 14.88 29 20361 311 53328365
Bone pain 112.94 14.88 117 20273 50605 53278071
Peripheral artery stenosis 111.70 14.88 29 20361 569 53328107
Intermittent claudication 109.66 14.88 37 20353 1839 53326837
Blood bilirubin increased 105.04 14.88 96 20294 35634 53293042
Malignant neoplasm progression 105.01 14.88 133 20257 71408 53257268
Myocardial infarction 104.16 14.88 157 20233 99197 53229479
Off label use 91.95 14.88 33 20357 472179 52856497
Thrombocytopenia 84.97 14.88 173 20217 138554 53190122
Rheumatoid arthritis 83.20 14.88 11 20379 314520 53014156
Chronic myeloid leukaemia recurrent 82.99 14.88 19 20371 214 53328462
Platelet count decreased 76.12 14.88 143 20247 107956 53220720
Acute myocardial infarction 74.56 14.88 77 20313 33158 53295518
Pancreatitis 74.46 14.88 90 20300 46052 53282624
Arteriosclerosis 71.84 14.88 46 20344 10065 53318611
Acute lymphocytic leukaemia recurrent 70.43 14.88 28 20362 2220 53326456
Myalgia 69.64 14.88 156 20234 133335 53195341
White blood cell count increased 67.86 14.88 86 20304 46159 53282517
Pruritus 62.03 14.88 249 20141 293583 53035093
Angina pectoris 59.88 14.88 64 20326 28661 53300015
Platelet count increased 59.65 14.88 49 20341 15758 53312918
Death 59.60 14.88 282 20108 356950 52971726
Labelled drug-food interaction medication error 58.93 14.88 11 20379 39 53328637
Normal newborn 56.88 14.88 35 20355 7144 53321532
Peripheral vascular disorder 51.53 14.88 31 20359 6077 53322599
Condition aggravated 50.92 14.88 25 20365 297109 53031567
Pancytopenia 50.49 14.88 109 20281 90819 53237857
Blast cell crisis 48.45 14.88 10 20380 66 53328610
Therapeutic response delayed 48.40 14.88 15 20375 567 53328109
Polymerase chain reaction positive 48.19 14.88 10 20380 68 53328608
Pericardial effusion 46.94 14.88 55 20335 27223 53301453
Exposure via partner 46.60 14.88 11 20379 143 53328533
Exposure via father 46.60 14.88 13 20377 338 53328338
Haematotoxicity 46.59 14.88 32 20358 7865 53320811
Splenomegaly 45.02 14.88 35 20355 10404 53318272
Myocardial ischaemia 44.70 14.88 38 20352 12806 53315870
Joint swelling 44.54 14.88 17 20373 234621 53094055
Hyperbilirubinaemia 43.21 14.88 35 20355 11034 53317642
Blood glucose increased 40.96 14.88 91 20299 77270 53251406
Cerebrovascular accident 40.05 14.88 109 20281 105065 53223611
Carotid artery stenosis 39.75 14.88 25 20365 5302 53323374
Dry skin 39.20 14.88 66 20324 45694 53282982
Drug hypersensitivity 38.79 14.88 27 20363 265215 53063461
Arterial disorder 38.38 14.88 15 20375 1136 53327540
Gastrointestinal stromal tumour 37.79 14.88 15 20375 1184 53327492
Xanthelasma 37.19 14.88 8 20382 66 53328610
Drug ineffective 37.02 14.88 174 20216 817071 52511605
Anaemia 34.70 14.88 202 20188 276516 53052160
Systemic lupus erythematosus 34.05 14.88 4 20386 125410 53203266
Thrombocytosis 34.02 14.88 23 20367 5509 53323167
Arthropathy 32.81 14.88 7 20383 141446 53187230
Coronary artery disease 32.40 14.88 51 20339 33386 53295290
Amylase increased 32.35 14.88 23 20367 5971 53322705
Palpitations 32.13 14.88 99 20291 102249 53226427
Bone marrow failure 32.09 14.88 48 20342 30067 53298609
Leukaemia recurrent 31.98 14.88 14 20376 1413 53327263
Basophil count increased 31.33 14.88 12 20378 861 53327815
Skin disorder 31.32 14.88 43 20347 24915 53303761
Gene mutation identification test positive 31.20 14.88 8 20382 149 53328527
Arterial occlusive disease 31.07 14.88 21 20369 5028 53323648
Food interaction 30.90 14.88 11 20379 642 53328034
Diabetes mellitus 30.34 14.88 65 20325 53834 53274842
Hypercholesterolaemia 29.66 14.88 30 20360 12596 53316080
Concomitant disease progression 28.95 14.88 15 20375 2203 53326473
Abdominal pain upper 28.89 14.88 133 20257 166158 53162518
Acute coronary syndrome 28.66 14.88 27 20363 10397 53318279
Alopecia 27.94 14.88 169 20221 234414 53094262
Cytopenia 27.64 14.88 25 20365 9145 53319531
Hypotension 27.52 14.88 34 20356 254042 53074634
Acute kidney injury 27.47 14.88 34 20356 253834 53074842
Peripheral artery occlusion 27.40 14.88 12 20378 1213 53327463
Peripheral ischaemia 27.19 14.88 19 20371 4800 53323876
Toxicity to various agents 26.39 14.88 27 20363 219571 53109105
Glossodynia 25.32 14.88 4 20386 100287 53228389
Pain in extremity 24.78 14.88 190 20200 284860 53043816
Concomitant disease aggravated 24.73 14.88 23 20367 8715 53319961
Pregnancy of partner 24.09 14.88 5 20385 34 53328642
Neoplasm malignant 23.36 14.88 38 20352 25563 53303113
Hepatic infection 23.25 14.88 8 20382 422 53328254
Blast cell count increased 23.19 14.88 8 20382 425 53328251
Collateral circulation 22.77 14.88 4 20386 9 53328667
Keratosis pilaris 22.76 14.88 5 20385 46 53328630
Therapeutic response decreased 21.92 14.88 53 20337 47516 53281160
Gamma-glutamyltransferase increased 21.87 14.88 43 20347 33512 53295164
Abdominal pain 21.36 14.88 169 20221 255734 53072942
Muscle spasms 21.35 14.88 105 20285 134690 53193986
Alanine aminotransferase increased 21.12 14.88 82 20308 95013 53233663
Sinusitis 21.08 14.88 20 20370 168544 53160132
Haemolytic transfusion reaction 20.67 14.88 4 20386 18 53328658
Product use issue 20.66 14.88 14 20376 139570 53189106
Gangrene 20.27 14.88 16 20374 4861 53323815
Musculoskeletal stiffness 20.17 14.88 11 20379 123357 53205319
Chest pain 20.13 14.88 133 20257 190052 53138624
Overdose 20.10 14.88 8 20382 107728 53220948
Confusional state 19.98 14.88 27 20363 194194 53134482
Blood lactate dehydrogenase increased 19.43 14.88 32 20358 21749 53306927
Delivery 19.32 14.88 8 20382 704 53327972
Pancreatic enzymes increased 19.20 14.88 8 20382 715 53327961
Hyponatraemia 18.78 14.88 9 20381 108598 53220078
Dyslipidaemia 18.58 14.88 17 20373 6310 53322366
Lower respiratory tract infection 18.25 14.88 6 20384 90975 53237701
Intentional product use issue 18.05 14.88 3 20387 72491 53256185
Leukocytosis 17.72 14.88 33 20357 24701 53303975
Transaminases increased 17.72 14.88 37 20353 30095 53298581
Gene mutation 17.68 14.88 9 20381 1274 53327402
Cardiac failure 17.44 14.88 72 20318 85772 53242904
Oxygen saturation decreased 17.37 14.88 4 20386 76721 53251955
Angiopathy 17.21 14.88 14 20376 4440 53324236
Calculus bladder 17.13 14.88 7 20383 596 53328080
Wound 16.75 14.88 7 20383 91550 53237126
Hyperglycaemia 16.72 14.88 43 20347 40041 53288635
Exposure during pregnancy 16.58 14.88 14 20376 124846 53203830
Haemoglobin decreased 16.37 14.88 99 20291 137208 53191468
Fall 16.31 14.88 76 20314 358364 52970312
Urinary tract infection 16.19 14.88 43 20347 239860 53088816
Coronary artery stenosis 16.14 14.88 14 20376 4845 53323831
Hepatic function abnormal 15.82 14.88 40 20350 36859 53291817
Fluid retention 15.57 14.88 51 20339 54350 53274326
Jaundice 15.29 14.88 35 20355 30278 53298398
Vertebral artery stenosis 15.29 14.88 4 20386 81 53328595
Impaired healing 15.25 14.88 3 20387 64202 53264474
Extremity necrosis 15.12 14.88 9 20381 1730 53326946
Thromboangiitis obliterans 14.93 14.88 3 20387 17 53328659
Dyspepsia 14.91 14.88 64 20326 77536 53251140

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Chronic myeloid leukaemia 597.41 14.97 170 21901 2614 32488841
Cytogenetic analysis abnormal 429.37 14.97 94 21977 438 32491017
Blast crisis in myelogenous leukaemia 397.01 14.97 90 21981 506 32490949
Second primary malignancy 370.81 14.97 149 21922 6792 32484663
Peripheral arterial occlusive disease 359.30 14.97 138 21933 5571 32485884
Electrocardiogram QT prolonged 353.33 14.97 258 21813 39383 32452072
Drug resistance 217.04 14.97 155 21916 22810 32468645
Intermittent claudication 208.99 14.97 73 21998 2239 32489216
Pleural effusion 197.17 14.97 255 21816 78737 32412718
Angina pectoris 196.40 14.97 166 21905 31260 32460195
Rash 157.60 14.97 400 21671 208933 32282522
Lipase increased 156.01 14.97 90 21981 9167 32482288
Myocardial infarction 140.15 14.97 281 21790 125395 32366060
Chronic myeloid leukaemia transformation 139.92 14.97 31 22040 154 32491301
Death 127.47 14.97 554 21517 381963 32109492
Coronary artery stenosis 118.37 14.97 77 21994 9716 32481739
Philadelphia chromosome positive 117.71 14.97 30 22041 294 32491161
Drug intolerance 112.60 14.97 154 21917 50081 32441374
Off label use 111.25 14.97 35 22036 306285 32185170
Chronic myeloid leukaemia recurrent 107.75 14.97 25 22046 158 32491297
Pancreatitis 93.19 14.97 122 21949 38029 32453426
Blood bilirubin increased 91.61 14.97 122 21949 38662 32452793
Malignant neoplasm progression 91.54 14.97 179 21892 78317 32413138
Peripheral artery stenosis 90.96 14.97 31 22040 881 32490574
Acute kidney injury 82.00 14.97 49 22022 293419 32198036
Arterial disorder 79.73 14.97 31 22040 1291 32490164
White blood cell count increased 79.59 14.97 118 21953 41284 32450171
Acute myocardial infarction 75.81 14.97 135 21936 55014 32436441
Platelet count decreased 73.77 14.97 207 21864 114384 32377071
Myocardial ischaemia 72.42 14.97 74 21997 17685 32473770
Coronary artery disease 71.32 14.97 124 21947 49582 32441873
Peripheral vascular disorder 70.02 14.97 44 22027 5228 32486227
Hypotension 66.28 14.97 32 22039 216078 32275377
Abdominal pain upper 63.74 14.97 141 21930 67197 32424258
Toxicity to various agents 63.33 14.97 21 22050 178020 32313435
Concomitant disease aggravated 57.63 14.97 40 22031 5613 32485842
Gastrointestinal stromal tumour 55.99 14.97 24 22047 1286 32490169
Chest pain 55.71 14.97 198 21873 123939 32367516
Carotid artery stenosis 53.18 14.97 36 22035 4850 32486605
Acute coronary syndrome 53.08 14.97 56 22015 13885 32477570
Polymerase chain reaction positive 52.82 14.97 13 22058 109 32491346
Thrombocytopenia 51.42 14.97 218 21853 148081 32343374
Blast cell crisis 51.30 14.97 12 22059 79 32491376
Gene mutation identification test positive 50.70 14.97 14 22057 191 32491264
Arterial stenosis 50.22 14.97 22 22049 1243 32490212
Splenomegaly 49.59 14.97 55 22016 14422 32477033
Concomitant disease progression 48.64 14.97 27 22044 2551 32488904
Peripheral artery occlusion 48.18 14.97 23 22048 1587 32489868
Exposure via father 46.33 14.97 12 22059 126 32491329
Gene mutation 45.25 14.97 19 22052 967 32490488
Loss of therapeutic response 43.52 14.97 13 22058 238 32491217
Bone pain 43.48 14.97 61 22010 20283 32471172
Pruritus 42.90 14.97 187 21884 128515 32362940
Arteriosclerosis 41.43 14.97 44 22027 10990 32480465
Labelled drug-food interaction medication error 39.63 14.97 9 22062 51 32491404
Drug interaction 38.82 14.97 55 22016 218130 32273325
Confusional state 38.33 14.97 25 22046 143090 32348365
Overdose 35.17 14.97 8 22063 87069 32404386
Fall 34.36 14.97 50 22021 196151 32295304
Peripheral ischaemia 32.81 14.97 29 22042 5782 32485673
Angina unstable 32.47 14.97 41 22030 12314 32479141
Amylase increased 31.79 14.97 29 22042 6026 32485429
Infarction 31.61 14.97 21 22050 2742 32488713
Paternal exposure during pregnancy 31.54 14.97 6 22065 11 32491444
Cerebral infarction 30.95 14.97 62 22009 27552 32463903
Myalgia 30.13 14.97 122 21949 81108 32410347
Blood glucose increased 30.01 14.97 105 21966 65136 32426319
Hyperglycaemia 29.34 14.97 74 21997 38317 32453138
Cerebral artery stenosis 28.33 14.97 10 22061 316 32491139
Hypercholesterolaemia 26.80 14.97 30 22041 7944 32483511
Dehydration 26.58 14.97 29 22042 128929 32362526
Tremor 26.48 14.97 11 22060 81266 32410189
Pain in extremity 26.33 14.97 154 21917 118747 32372708
Condition aggravated 25.95 14.97 41 22030 155620 32335835
Drug hypersensitivity 25.46 14.97 9 22062 73391 32418064
Somnolence 25.33 14.97 20 22051 103777 32387678
Hallucination 25.31 14.97 3 22068 52616 32438839
Pericardial effusion 25.01 14.97 51 22020 22951 32468504
Therapeutic response decreased 24.18 14.97 54 22017 25866 32465589
Cerebrovascular accident 23.99 14.97 119 21952 86201 32405254
Chloroma 23.93 14.97 10 22061 503 32490952
Ischaemia 23.79 14.97 22 22049 4650 32486805
Clonal evolution 23.60 14.97 7 22064 125 32491330
Hepatic infection 23.31 14.97 10 22061 537 32490918
Arterial thrombosis 23.24 14.97 14 22057 1542 32489913
Gangrene 22.97 14.97 22 22049 4860 32486595
Hyponatraemia 22.83 14.97 11 22060 74502 32416953
Acute lymphocytic leukaemia 22.80 14.97 19 22052 3499 32487956
Acoustic neuroma 22.76 14.97 7 22064 142 32491313
Product blister packaging issue 22.59 14.97 6 22065 70 32491385
Coronary artery occlusion 22.43 14.97 33 22038 11452 32480003
Basophil count increased 22.38 14.97 9 22062 410 32491045
Agitation 21.67 14.97 6 22065 57230 32434225
Leukocytosis 20.90 14.97 48 22023 23419 32468036
Necrosis 20.70 14.97 22 22049 5497 32485958
Rheumatoid arthritis 20.32 14.97 3 22068 44541 32446914
Fatigue 20.21 14.97 342 21729 350359 32141096
Atrial fibrillation 20.18 14.97 142 21929 116562 32374893
Arteritis 20.18 14.97 8 22063 351 32491104
Blast cells present 20.14 14.97 9 22062 533 32490922
Gamma-glutamyltransferase increased 20.13 14.97 56 22015 30726 32460729
Myeloproliferative neoplasm 20.06 14.97 9 22062 538 32490917
Gelatinous transformation of the bone marrow 19.90 14.97 4 22067 11 32491444
Carotid arteriosclerosis 19.59 14.97 11 22060 1062 32490393
Chest discomfort 19.05 14.97 76 21995 50154 32441301
Pancreatic toxicity 18.89 14.97 3 22068 0 32491455
Intentional overdose 18.53 14.97 3 22068 41598 32449857
Diabetes mellitus 18.48 14.97 70 22001 45103 32446352
B-cell small lymphocytic lymphoma 18.37 14.97 6 22065 149 32491306
Cytopenia 18.34 14.97 28 22043 10036 32481419
Acquired gene mutation 18.06 14.97 11 22060 1236 32490219
Acne 17.97 14.97 28 22043 10214 32481241
Central nervous system leukaemia 17.97 14.97 7 22064 293 32491162
Asthma 17.88 14.97 4 22067 44061 32447394
Delirium 17.87 14.97 4 22067 44042 32447413
Abdominal pain 17.75 14.97 167 21904 149362 32342093
Leukaemia recurrent 17.65 14.97 12 22059 1627 32489828
Seizure 17.63 14.97 27 22044 103827 32387628
Arterial occlusive disease 17.59 14.97 18 22053 4305 32487150
Vascular stenosis 17.52 14.97 6 22065 173 32491282
Rectosigmoid cancer 17.49 14.97 6 22065 174 32491281
Muscle spasms 17.42 14.97 94 21977 70324 32421131
Bone marrow failure 16.71 14.97 52 22019 30352 32461103
Neoplasm malignant 16.13 14.97 38 22033 18847 32472608
Febrile neutropenia 15.94 14.97 36 22035 119530 32371925
Nipple swelling 15.60 14.97 3 22068 6 32491449
Plasma cell myeloma 15.49 14.97 10 22061 57604 32433851
Prinzmetal angina 15.42 14.97 9 22062 935 32490520
Intentional product misuse 15.19 14.97 3 22068 36048 32455407
Aggression 15.15 14.97 4 22067 39385 32452070

Pharmacologic Action:

SourceCodeDescription
ATC L01EA03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
FDA MoA N0000020009 Bcr-Abl Tyrosine Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
FDA MoA N0000187063 Cytochrome P450 2C8 Inducers
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000191272 UGT1A1 Inhibitors
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:38637 protein tyrosine kinase inhibitor
CHEBI has role CHEBI:149553 anti-coronaviral agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic phase chronic myeloid leukemia indication 413847001
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Chronic Myelocytic Leukemia Accelerated Phase indication
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Hyperbilirubinemia contraindication 14783006 DOID:2741
Torsades de pointes contraindication 31722008
Hypertensive disorder contraindication 38341003 DOID:10763
Hypokalemia contraindication 43339004
Gastrectomy contraindication 53442002
Diabetes mellitus contraindication 73211009 DOID:9351
Pancreatitis contraindication 75694006 DOID:4989
Hyperglycemia contraindication 80394007 DOID:4195
Hyponatremia contraindication 89627008
Prolonged QT interval contraindication 111975006
Liver function tests abnormal contraindication 166603001
Hypomagnesemia contraindication 190855004
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Elevated Serum Lipase contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.89 acidic
pKa2 6.03 Basic
pKa3 3.97 Basic
pKa4 2.2 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 7169791 July 4, 2023 A METHOD FOR THE TREATMENT OF LEUKEMIAS
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 8389537 July 18, 2026 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 8415363 July 18, 2026 TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 8415363 July 18, 2026 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 9061029 April 7, 2032 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL 9061029 April 7, 2032 TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) BY ADMINISTERING NILOTINIB DISPERSED IN A FRUIT PREPARATION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL March 22, 2025 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH CHRONIC PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA WITH RESISTANCE OR INTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR THERAPY
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL March 22, 2025 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) IN CHRONIC PHASE
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL Sept. 22, 2025 PEDIATRIC EXCLUSIVITY
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL Sept. 23, 2028 TREATMENT OF PEDIATRIC PATIENTS GREATER THAN OR EQUAL TO 1 YEAR OF AGE WITH ACCELERATED PHASE PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+ CML) WITH RESISTANCE ORINTOLERANCE TO PRIOR TYROSINE-KINASE INHIBITOR (TKI) THERAPY
EQ 50MG BASE TASIGNA NOVARTIS N022068 March 22, 2018 RX CAPSULE ORAL March 23, 2029 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Tyrosine-protein kinase ABL1 Kinase INHIBITOR Kd 8.44 CHEMBL CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 6.35 CHEMBL
Carbonic anhydrase 2 Enzyme Ki 8.39 CHEMBL
Carbonic anhydrase 1 Enzyme Ki 7.53 CHEMBL
Carbonic anhydrase 4 Enzyme Ki 6.35 CHEMBL
Ribosyldihydronicotinamide dehydrogenase [quinone] Enzyme IC50 6.42 CHEMBL
Carbonic anhydrase 9 Enzyme Ki 7.38 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 6.52 CHEMBL
Platelet-derived growth factor receptor beta Kinase Kd 7.80 CHEMBL
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 5.26 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 4.83 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 7 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 5.72 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 7.33 CHEMBL
Tyrosine-protein kinase Yes Kinase Kd 5.96 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.80 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 6.64 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 5.41 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 6.24 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 4.40 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.06 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.35 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.13 CHEMBL
Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Kinase Kd 6.48 CHEMBL
Insulin receptor Kinase Ki 5.39 PDSP
Mitogen-activated protein kinase 8 Kinase Kd 6.35 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 6.41 CHEMBL
Carbonic anhydrase 3 Enzyme Ki 6.35 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 6.34 CHEMBL
Mitogen-activated protein kinase 10 Kinase Kd 5.70 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Ki 5.07 PDSP
Tyrosine-protein kinase CSK Kinase Kd 5.62 CHEMBL
Angiopoietin-1 receptor Kinase Kd 6 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 7.43 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 7 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Ki 5.32 PDSP
Carbonic anhydrase 14 Enzyme Ki 6.65 CHEMBL
Fibroblast growth factor receptor 1 Kinase Ki 5.10 PDSP
Serine/threonine-protein kinase 10 Kinase Kd 5.17 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 7.59 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 7.44 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 5.72 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 6.48 CHEMBL
Fibroblast growth factor receptor 2 Kinase Ki 5.14 PDSP
Ephrin type-A receptor 6 Kinase Kd 6.19 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 6.49 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 6.96 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.34 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 7.07 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.68 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 5.89 CHEMBL
Dual specificity protein kinase CLK4 Kinase Kd 5.15 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.24 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 8.96 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 6.14 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 6.31 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 6.19 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 7.96 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 6 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.22 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.44 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.22 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.05 CHEMBL
Tyrosine-protein kinase Blk Kinase Kd 6.30 CHEMBL
Serine/threonine-protein kinase MRCK beta Kinase Kd 6.04 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 6.23 CHEMBL
Ephrin type-B receptor 3 Kinase Kd 6 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.30 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 5.33 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.77 CHEMBL
Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma Kinase Kd 5.06 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.72 CHEMBL
Bcr/Abl fusion protein Kinase IC50 9.48 CHEMBL
Ferrochelatase, mitochondrial Enzyme Kd 5.38 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase Kd 5.89 CHEMBL
Mast/stem cell growth factor receptor Kit Kinase Kd 7.77 CHEMBL
Integrin-linked protein kinase Kinase Kd 7.70 CHEMBL
Carbonic anhydrase 13 Enzyme Ki 5.33 CHEMBL
Carbonic anhydrase 15 Enzyme Ki 7.10 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.10 CHEMBL

External reference:

IDSource
4026964 VUID
N0000176124 NUI
D06413 KEGG_DRUG
923288-90-8 SECONDARY_CAS_RN
4026964 VANDF
C1721377 UMLSCUI
CHEBI:52172 CHEBI
NIL PDB_CHEM_ID
CHEMBL255863 ChEMBL_ID
CHEMBL1201740 ChEMBL_ID
DB04868 DRUGBANK_ID
C498826 MESH_SUPPLEMENTAL_RECORD_UI
5697 IUPHAR_LIGAND_ID
8654 INN_ID
F41401512X UNII
644241 PUBCHEM_CID
662281 RXNORM
127956 MMSL
24733 MMSL
d07057 MMSL
012401 NDDF
427941004 SNOMEDCT_US
428468009 SNOMEDCT_US
438943005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0526 CAPSULE 200 mg ORAL NDA 33 sections
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0592 CAPSULE 150 mg ORAL NDA 33 sections
Tasigna HUMAN PRESCRIPTION DRUG LABEL 1 0078-0951 CAPSULE 50 mg ORAL NDA 33 sections